Cover Page - USD ($) |
12 Months Ended | ||
|---|---|---|---|
Dec. 31, 2024 |
Apr. 30, 2025 |
Jun. 30, 2024 |
|
| Cover [Abstract] | |||
| Document Type | 10-K/A | ||
| Amendment Flag | true | ||
| Amendment Description | Alaunos Therapeutics, Inc. (which may be referred to herein as “we,” “us” or the “Company”) is filing this Amendment No. 1 to its Annual Report on Form 10-K/A (this “Amended Filing”) to amend its Annual Report on Form 10-K for the fiscal year ended December 31, 2024 (the “Original Filing”), as originally filed with the U.S. Securities and Exchange Commission (the “SEC”) on March 31, 2025 (the “Original Filing Date”), to include the information required by Items 10 through 14 of Part III of Form 10-K (the “Part III Information”). The Part III Information was previously omitted from the Original Filing in reliance on General Instruction G(3) to Form 10-K, which permits the Part III Information to be incorporated by reference in the Form 10-K by reference from the Company’s definitive proxy statement if such statement is filed no later than 120 days after the end of the fiscal year covered by the Original Filing. The Company is filing this Amended Filing to include the Part III Information because it may not file a definitive proxy statement containing such information within 120 days after the end of the fiscal year covered by the Original Filing. The reference on the cover of the Original Filing to the incorporation by reference to portions of the Company’s definitive proxy statement into Part III of the Original Filing is hereby deleted.This Amendment hereby amends Part III, Items 10 through 14, and Part IV, Item 15 of the Original Filing. In addition, pursuant to Rule 12b-15 under Securities Exchange Act of 1934, as amended, this Amended Filing also contains new certifications pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, which are attached hereto. Because no financial statements have been amended by or included in this Amended Filing and this Amended Filing does not contain or amend any disclosure with respect to Items 307 and 308 of Regulation S-K, paragraphs 3, 4 and 5 of the certifications have been omitted. | ||
| Document Period End Date | Dec. 31, 2024 | ||
| Document Fiscal Year Focus | 2024 | ||
| Document Fiscal Period Focus | FY | ||
| Entity Registrant Name | Alaunos Therapeutics, Inc. | ||
| Entity Central Index Key | 0001107421 | ||
| Current Fiscal Year End Date | --12-31 | ||
| Entity Filer Category | Non-accelerated Filer | ||
| Trading Symbol | TCRT | ||
| Document Transition Report | false | ||
| Document Annual Report | true | ||
| Security Exchange Name | NASDAQ | ||
| Title of 12(b) Security | Common Stock | ||
| Entity File Number | 001-33038 | ||
| Entity Incorporation, State or Country Code | DE | ||
| Entity Address, Address Line One | 2617 Bissonnet Street, | ||
| Entity Address, Address Line Two | Suite 233 | ||
| Entity Address, City or Town | Houston | ||
| Entity Address, State or Province | TX | ||
| Entity Address, Postal Zip Code | 77005 | ||
| Entity Tax Identification Number | 84-1475642 | ||
| City Area Code | 346 | ||
| Local Phone Number | 355-4099 | ||
| Entity Well-known Seasoned Issuer | No | ||
| Entity Current Reporting Status | Yes | ||
| Entity Voluntary Filers | No | ||
| Entity Interactive Data Current | Yes | ||
| Entity Shell Company | false | ||
| Entity Small Business | true | ||
| Entity Emerging Growth Company | false | ||
| Document Financial Statement Error Correction [Flag] | false | ||
| ICFR Auditor Attestation Flag | false | ||
| Entity Common Stock, Shares Outstanding | 1,639,521 | ||
| Entity Public Float | $ 10,801,553 |